Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1709)
  2. Journal Article (1439)
  3. Review (82)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3394)
  2. Solid Tumor Oncology Division (3394)
  3. GSK Faculty (1071)
  4. Department of Pathology and Laboratory Medicine (809)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (662)
  6. Human Oncology and Pathogenesis Program (635)

More Groups

People
  1. Mark Kris (872)
  2. Alexander Drilon (637)
  3. Gregory Riely (605)
  4. Charles Rudin (495)
  5. Marc Ladanyi (418)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (114)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (703)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (158)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (782)
  2. Elsevier Inc. (738)
  3. American Association for Cancer Research (386)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (79)

More Publishers

Results (3394)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Global RET registry (GLORY): Activity of RET-directed targeted therapies in RET-rearranged lung cancers
    Meeting Abstract

    Gautschi, O.; Milia-Baron, J.; Filleron, T.; Wolf, J.; Carbone, D.; Owen, D.; Camidge, D. R.; Narayanan, V.; Doebele, R.; Besse, B.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Neratinib +/- temsirolimus in HER2-mutant lung cancers: An international, randomized phase II study
    Meeting Abstract

    Gandhi, L.; Besse, B.; Mazieres, J.; Waciar, S.; Cortot, A.; Barlesi, F.; Quoix, E.; Otterson, G.; Ettinger, D.; Horn, L.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Updated efficacy and safety data from the phase 2 NP28761 study of alectinib in ALK-positive non-small-cell lung cancer
    Meeting Abstract

    Camidge, D. R.; Gadgeel, S.; Ou, S. H.; Gandhi, L.; Riely, G.; Cetnar, J.; West, H.; Socinski, M.; Chiappori, A.; Mekhail, T.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • A highly sensitive next-generation sequencing platform for detection of NSCLC EGFR T790M mutation in urine and plasma
    Meeting Abstract

    Wakelee, H.; Melnikova, V.; Karlovich, C.; Gadgeel, S.; Reckamp, K.; Goldman, J. W.; Camidge, D. R.; PeĢrol, M.; Ou, S. H.; Liu, S.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Nivolumab alone or with ipilimumab in recurrent small cell lung cancer (SCLC): 2-year survival and apdated analyses from the CheckMate 032 trial
    Meeting Abstract

    Hellmann, M.; Antonia, S.; Ponce, S.; Ott, P.; Calvo, E.; Taylor, M.; Ready, N.; Hann, C.; De Braud, F.; Eder, J. P.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Improved small cell lung cancer (SCLC) response rates with veliparib and temozolomide: Results from a phase II trial
    Meeting Abstract

    Byers, L. A.; Krug, L.; Waqar, S.; Dowlati, A.; Hann, C.; Chiappori, A.; Owonikoko, T.; Woo, K.; Bensman, Y.; Hurtado, B.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Single-agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC), in small-cell lung cancer (SCLC)
    Meeting Abstract

    Spigel, D.; Pietanza, M. C.; Bauer, T.; Ready, N.; Morgensztern, D.; Glisson, B. S.; Byers, L. A.; Johnson, M.; Burris, H.; Robert, F.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • A phase 2 study of cabozantinib for patients with advanced RET-rearranged lung cancers
    Meeting Abstract

    Drilon, A.; Somwar, R.; Smith, R.; Delasos, L.; Albano, M.; Van Voorthuyson, M.; Wang, L.; Rekhtman, N.; Ni, A.; Plodkowski, A.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Tumor mutation burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L+ NSCLC patients
    Meeting Abstract

    Kowanetz, M.; Zou, W.; Shames, D.; Cummings, C.; Rizvi, N.; Spira, A.; Frampton, G.; Leveque, V.; Flynn, S.; Mocci, S.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • First-line nivolumab monotherapy and nivolumab plus ipilimumab in patients with advanced NSCLC: Long-term outcomes from CheckMate 012
    Meeting Abstract

    Gettinger, S.; Rizvi, N.; Chow, L.; Borghaei, H.; Brahmer, J.; Shepherd, F.; Ready, N.; Gerber, D.; Antonia, S.; Goldman, J. W.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save